Skip to main content
. Author manuscript; available in PMC: 2023 Sep 1.
Published in final edited form as: Clin Pharmacol Ther. 2022 Jun 22;112(3):573–592. doi: 10.1002/cpt.2670

Figure 1:

Figure 1:

Correlation between reduction in systemic CL and renal or non-renal CL for DDIs involving intravenous administration of P-gp substrate drugs. Each symbol represents one clinical DDI case (Table 1). Numbers in the symbol represent inhibitors in the DDI study (1: amiodarone, 2: cyclosporine, 3: quinidine, 4: quinine, 5: ritonavir, 6: spironolactone, 7: valspodar (PSC833), 8: verapamil). CL, clearance; DDI, drug-drug interaction.